Immunovia completes analytical validation of its next-generation pancreatic cancer test
Rhea-AI Summary
Immunovia (IMMNOV: Nasdaq Stockholm) has completed the analytical validation of its next-generation test for early-stage pancreatic cancer detection. The validation demonstrated excellent results across 23 key performance attributes, meeting CLIA and CAP accreditation standards. Key highlights include high precision, linearity, sensitivity, stability, and robustness. The test uses an automated ELISA analyzer, enhancing performance and throughput compared to previous methods.
Following this success, Immunovia has initiated a large-scale clinical validation study to assess the test's accuracy in detecting stage 1 and 2 pancreatic cancer, expected to be completed by December 2024. This study will provide important insights into the test's clinical performance, including sensitivity and specificity.
Positive
- Successful completion of analytical validation for next-generation pancreatic cancer test
- Test demonstrated excellent performance across 23 key attributes
- Automated ELISA analyzer enhances performance and throughput
- Initiation of large-scale clinical validation study
Negative
- None.
Insights
The completion of analytical validation for Immunovia's next-generation pancreatic cancer test is a significant milestone in the field of early cancer detection. The test's performance across key parameters like precision, linearity, sensitivity, stability and robustness is promising. Notably, the use of an automated ELISA analyzer enhances both performance and throughput compared to previous methods.
The test's ability to detect biomarkers at low levels could be important for identifying early-stage pancreatic cancer, potentially improving survival rates. However, it's important to note that while analytical validation is a critical step, it doesn't yet prove clinical efficacy. The upcoming clinical validation study, set to complete by December 2024, will be pivotal in determining the test's real-world accuracy in detecting stage 1 and 2 pancreatic cancer.
For investors, this development signals progress in Immunovia's product pipeline, but it's essential to await clinical validation results before drawing conclusions about the test's market potential. The
Immunovia's announcement of completing analytical validation for its next-generation pancreatic cancer test is a positive development for the company's future prospects. This milestone potentially positions Immunovia to capture a share of the lucrative early cancer detection market, particularly in the USA, where 1.8 million individuals are estimated to be at high risk for pancreatic cancer.
However, investors should exercise caution. While this news is promising, the true value proposition lies in the upcoming clinical validation results expected by December 2024. These results will be important in determining the test's commercial viability and potential for regulatory approval. The market's reaction to this news may be tempered until more concrete clinical data is available.
From a financial perspective, successful development and commercialization of this test could significantly impact Immunovia's revenue streams. However, the path from validation to market is often long and costly in the medical diagnostics sector. Investors should closely monitor the company's cash position and burn rate as it progresses through clinical validation and potential regulatory processes.
The biomarkers that make up Immunovia's next-generation test demonstrated excellent performance in a series of experiments. These experiments evaluated over 23 key performance attributes of the next-generation test according to guidelines set by the Clinical and Laboratory Standards Institute (CLSI) under the guidance of Immunovia's lab director, Lisa Ford, Ph.D. The experiments were designed to meet the stringent requirements of the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) accreditation standards, ensuring that the test meets the highest industry benchmarks.
Key highlights of the analytical validation include,
- Precision: The test demonstrated high precision and reproducibility across multiple testing runs, ensuring reliable results.
- Linearity: The test provided accurate readings at varying biomarker concentrations.
- Sensitivity: The assay exhibited high sensitivity, enabling detection of the target biomarkers even at low levels.
- Stability: The biomarkers remained stable under various conditions (e.g., different temperatures), maintaining their integrity and ensuring accurate measurement.
- Robustness: The test showed consistent performance across different batches of testing supplies and laboratory settings, confirming its robustness.
The analytical validation was conducted using an automated ELISA analyzer, which significantly enhances both performance and throughput compared to Immunovia's prior IMMray platform as well as standard manual ELISA tests.
"We are happy to announce that our analytical validation results confirm the strong performance of our next-generation test. This achievement validates the quality of our analytical method and marks an important milestone to provide a reliable, convenient test that could ultimately improve patient outcomes by enabling early detection of pancreatic cancer. We are excited to be moving to the next phase, clinical validation," says Lisa Ford, Ph.D., Lab Director at Immunovia.
Following the successful completion of the analytical validation, Immunovia has initiated a large-scale clinical validation study to assess the accuracy of its next-generation test in detecting stage 1 and 2 pancreatic cancer. This clinical validation is expected to be completed by December 2024. The results will provide crucial insights into the test's clinical performance, including its sensitivity and specificity.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-completes-analytical-validation-of-its-next-generation-pancreatic-cancer-test-302265344.html
SOURCE Immunovia AB
FAQ
What are the key results of Immunovia's (IMMNOV) analytical validation for its pancreatic cancer test?
When is Immunovia (IMMNOV) expected to complete the clinical validation of its pancreatic cancer test?
What technology does Immunovia (IMMNOV) use for its next-generation pancreatic cancer test?
What is the target market for Immunovia's (IMMNOV) pancreatic cancer test?
